SI3187225T1 - Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo HIV integraze - Google Patents

Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo HIV integraze

Info

Publication number
SI3187225T1
SI3187225T1 SI200632418T SI200632418T SI3187225T1 SI 3187225 T1 SI3187225 T1 SI 3187225T1 SI 200632418 T SI200632418 T SI 200632418T SI 200632418 T SI200632418 T SI 200632418T SI 3187225 T1 SI3187225 T1 SI 3187225T1
Authority
SI
Slovenia
Prior art keywords
inhibitory activity
hiv integrase
integrase inhibitory
polycyclic carbamoylpyridone
carbamoylpyridone derivative
Prior art date
Application number
SI200632418T
Other languages
English (en)
Slovenian (sl)
Inventor
Brian Alvin Johns
Takashi Kawasuji
Teruhiko Taishi
Yoshiyuki Taoda
Original Assignee
Viiv Healthcare Company
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3187225(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Company, Shionogi & Co., Ltd. filed Critical Viiv Healthcare Company
Publication of SI3187225T1 publication Critical patent/SI3187225T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200632418T 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo HIV integraze SI3187225T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
EP17156762.1A EP3187225B1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (1)

Publication Number Publication Date
SI3187225T1 true SI3187225T1 (sl) 2022-04-29

Family

ID=37215098

Family Applications (6)

Application Number Title Priority Date Filing Date
SI200632418T SI3187225T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo HIV integraze
SI200631747T SI2465580T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo
SI200632268T SI3045206T1 (en) 2005-04-28 2006-04-28 A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
SI200632344T SI3284520T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo
SI200632410T SI3372281T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze
SI200631703T SI1874117T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo

Family Applications After (5)

Application Number Title Priority Date Filing Date
SI200631747T SI2465580T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo
SI200632268T SI3045206T1 (en) 2005-04-28 2006-04-28 A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
SI200632344T SI3284520T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo
SI200632410T SI3372281T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze
SI200631703T SI1874117T1 (sl) 2005-04-28 2006-04-28 Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo

Country Status (30)

Country Link
US (22) US8129385B2 (enExample)
EP (9) EP3284520B1 (enExample)
JP (2) JP4295353B2 (enExample)
KR (4) KR101363875B1 (enExample)
AU (1) AU2006239177B8 (enExample)
BE (1) BE2021C519I2 (enExample)
BR (1) BRPI0610030B8 (enExample)
CA (1) CA2606282C (enExample)
CY (7) CY1115151T1 (enExample)
DK (6) DK3372281T3 (enExample)
EA (1) EA014162B1 (enExample)
ES (7) ES2446324T3 (enExample)
FI (1) FIC20210017I1 (enExample)
FR (1) FR14C0041I2 (enExample)
HK (2) HK1249742A1 (enExample)
HU (6) HUE037795T2 (enExample)
IL (4) IL186555A (enExample)
LT (5) LT3372281T (enExample)
LU (2) LU92446I2 (enExample)
MA (1) MA29460B1 (enExample)
MX (2) MX302718B (enExample)
NL (2) NL300676I2 (enExample)
NO (5) NO339525B1 (enExample)
NZ (1) NZ562339A (enExample)
PL (5) PL2465580T3 (enExample)
PT (5) PT1874117E (enExample)
SI (6) SI3187225T1 (enExample)
TW (1) TWI378931B (enExample)
VN (1) VN34404A1 (enExample)
WO (1) WO2006116764A1 (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360222T3 (es) 2003-12-24 2011-06-02 Biota Scientific Management Pty. Ltd. Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial.
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
JP4295353B2 (ja) 2005-04-28 2009-07-15 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
WO2006121831A2 (en) 2005-05-10 2006-11-16 Merck & Co., Inc. Hiv integrase inhibitors
EP1937678B1 (en) 2005-10-04 2011-07-27 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
JP5131689B2 (ja) 2005-10-27 2013-01-30 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
US8377960B2 (en) 2007-11-15 2013-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
RU2503679C2 (ru) * 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011816A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2320909B8 (en) 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP3210603A1 (en) 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2010068262A1 (en) * 2008-12-11 2010-06-17 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP2370419B1 (en) * 2008-12-11 2017-09-27 Shionogi&Co., Ltd. Maltol ether processes and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PL2444400T3 (pl) * 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
EA019558B1 (ru) 2009-10-13 2014-04-30 Эланко Энимал Хэлс Аиэлэнд Лимитед Макроциклические ингибиторы интегразы
NZ627827A (en) * 2010-01-27 2016-02-26 Viiv Healthcare Co Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
SG183484A1 (en) * 2010-02-26 2012-09-27 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
EP3127908B1 (en) * 2010-08-05 2018-11-28 Shionogi & Co., Ltd Process for preparing compound having hiv integrase inhibitory activity
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
HRP20181250T1 (hr) 2010-09-24 2018-10-05 Shionogi & Co., Ltd. Predlijek iz supstituiranog policikličkog derivata karbamoilpiridona
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
PL2742051T3 (pl) 2011-09-14 2017-06-30 Mapi Pharma Limited Amorficzna postać soli sodowej dolutegrawiru
EP2774928B1 (en) * 2011-10-12 2017-08-30 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
AP2014007805A0 (en) 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
SG11201504982PA (en) * 2012-12-27 2015-07-30 Japan Tobacco Inc SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2956123A1 (en) 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20151900A1 (es) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EP3016935B1 (en) * 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
NO2865735T3 (enExample) 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP3049081B1 (en) 2013-09-27 2019-11-27 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2015120133A1 (en) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
WO2015139591A1 (zh) * 2014-03-19 2015-09-24 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
IN2014MU00916A (enExample) 2014-03-20 2015-09-25 Cipla Ltd
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
NO2717902T3 (enExample) * 2014-06-20 2018-06-23
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016027879A1 (ja) 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
EP3203995A4 (en) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
CA2975884A1 (en) 2015-02-06 2016-08-11 Mylan Laboratories Limited Processes for the preparation of dolutegravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (en) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
EP3277691B1 (en) * 2015-04-02 2019-01-30 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AU2016256125B9 (en) * 2015-04-28 2020-02-20 Shionogi And Co., Ltd. Substituted polycyclic pyridone derivative and prodrug thereof
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
WO2017029642A2 (en) 2015-08-19 2017-02-23 Laurus Labs Private Limited Novel polymorphs of dolutegravir and salts thereof
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017109649A1 (en) 2015-12-21 2017-06-29 Lupin Limited Process for the preparation of hiv integrase inhibitors
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
EP4299133A3 (en) * 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
EP3496724B8 (en) * 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
EP3515438B1 (en) * 2016-09-21 2022-03-02 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN110062627A (zh) 2016-12-02 2019-07-26 默沙东公司 可用作hiv整合酶抑制剂的三环杂环化合物
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
CN110582504A (zh) 2017-02-16 2019-12-17 桑多斯股份公司 卡博特韦钠的晶形
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
AU2018304591A1 (en) 2017-07-21 2020-03-05 Janssen Sciences Ireland Unlimited Company Regimens for treating hiv infections and aids
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
MX2020003469A (es) 2017-10-06 2020-08-03 Shionogi & Co Proceso estereoselectivo para preparar derivados de piridona policiclicos sustituidos.
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
TWI880373B (zh) * 2018-05-31 2025-04-11 日商鹽野義製藥股份有限公司 多環性吡啶并三𠯤衍生物
EP4257137A3 (en) 2018-05-31 2023-11-01 Shionogi & Co., Ltd Polycyclic carbamoylpyridone derivatives for the treatment of hiv
SG11202011386QA (en) * 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
WO2020012408A2 (en) 2018-07-12 2020-01-16 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2020086555A1 (en) 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
US20220175936A1 (en) 2018-11-29 2022-06-09 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
MX2022006940A (es) 2019-12-09 2022-07-11 Viiv Healthcare Co Composiciones farmaceuticas.
IL295677A (en) * 2020-02-24 2022-10-01 Gilead Sciences Inc Tetracyclic compounds for treating hiv infection
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US20230321089A1 (en) 2020-09-01 2023-10-12 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
US12421235B2 (en) 2020-09-30 2025-09-23 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
EP4255472A2 (en) 2020-12-07 2023-10-11 VIIV Healthcare Company Combination therapy
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
US20250188091A1 (en) 2021-06-03 2025-06-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pyridone compound having integrase inhibitory activity and pharmaceutical use thereof
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (en) 2021-12-03 2023-06-08 Viiv Healthcase Company Process of synthesizing (r)-3-aminobutan-1-ol
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024153203A1 (en) * 2023-01-18 2024-07-25 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2001526265A (ja) 1997-12-22 2001-12-18 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド
AU2001262732A1 (en) † 2000-06-14 2001-12-24 Shionogi And Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
ATE364385T1 (de) 2000-10-12 2007-07-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
EP2181985B1 (en) 2001-08-10 2011-10-26 Shionogi & Co., Ltd. Antiviral Agent
DK1441734T3 (da) 2001-10-26 2007-06-11 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
CA2463976C (en) 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7279487B2 (en) 2002-01-17 2007-10-09 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
AU2003257822A1 (en) 2002-08-13 2004-04-30 Shionogi And Co., Ltd. Heterocyclic compound having hiv integrase inhibitory activity
JP2006506352A (ja) * 2002-09-11 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物
KR20050087865A (ko) * 2002-12-27 2005-08-31 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
EP1622615A4 (en) 2003-05-13 2009-02-18 Smithkline Beecham Corp INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
JP4859676B2 (ja) 2004-02-11 2012-01-25 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害剤
EP1725102A4 (en) † 2004-03-09 2009-04-29 Merck & Co Inc HIV integrase
CA2557926A1 (en) 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
CN1964975B (zh) 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
EP1852434B1 (en) * 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
CN101146811B (zh) * 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
JP4295353B2 (ja) * 2005-04-28 2009-07-15 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
WO2007019098A2 (en) 2005-08-04 2007-02-15 Smithkline Beecham Corporation Hiv integrase inhibitors
JP5131689B2 (ja) * 2005-10-27 2013-01-30 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体

Also Published As

Publication number Publication date
ES2446324T3 (es) 2014-03-07
CY1122052T1 (el) 2020-10-14
TW200716635A (en) 2007-05-01
DK3284520T3 (da) 2019-09-16
US20160137666A1 (en) 2016-05-19
ES2437268T3 (es) 2014-01-09
EP3187225A1 (en) 2017-07-05
SI1874117T1 (sl) 2014-01-31
MX312216B (en) 2013-08-12
LUC00210I2 (enExample) 2022-10-07
EP1874117A1 (en) 2008-01-09
US20240279238A1 (en) 2024-08-22
HUE044978T2 (hu) 2019-11-28
US20160207939A1 (en) 2016-07-21
FIC20210017I1 (fi) 2021-06-10
EP2465580B1 (en) 2013-12-18
NO2023042I1 (no) 2023-11-08
US11267823B2 (en) 2022-03-08
NO20075165L (no) 2007-11-22
DK1874117T3 (da) 2013-09-23
NL300676I2 (enExample) 2016-10-11
SI3372281T1 (sl) 2021-11-30
PT3372281T (pt) 2021-10-14
HK1251191A1 (en) 2019-01-25
BRPI0610030B1 (pt) 2020-09-15
KR101504998B1 (ko) 2015-03-23
EP3045206B2 (en) 2023-02-15
US20170253616A1 (en) 2017-09-07
HUS1400039I1 (hu) 2016-08-29
NO2017010I1 (no) 2017-03-27
PT1874117E (pt) 2013-10-17
EP3045206A1 (en) 2016-07-20
JP2009079058A (ja) 2009-04-16
BRPI0610030B8 (pt) 2022-01-11
PL3284520T3 (pl) 2020-01-31
EP3284519A1 (en) 2018-02-21
EP1874117A4 (en) 2009-12-30
US9273065B2 (en) 2016-03-01
SI3045206T1 (en) 2018-07-31
US20170260203A1 (en) 2017-09-14
CY1116331T1 (el) 2017-02-08
EP3284520A1 (en) 2018-02-21
US8778943B2 (en) 2014-07-15
NO340111B1 (no) 2017-03-13
MA29460B1 (fr) 2008-05-02
NO2021018I1 (no) 2021-05-10
PT3045206T (pt) 2018-07-05
IL186555A0 (en) 2008-01-20
EA014162B1 (ru) 2010-10-29
EP3045206B1 (en) 2018-03-28
FR14C0041I1 (enExample) 2014-06-27
PL1874117T3 (pl) 2014-01-31
IL225207A (en) 2017-11-30
KR101848819B1 (ko) 2018-04-16
ES2567197T3 (es) 2016-04-20
US20120115875A1 (en) 2012-05-10
CY1124601T1 (el) 2022-07-22
KR20160003889A (ko) 2016-01-11
NL301109I2 (nl) 2021-09-15
PL3372281T3 (pl) 2021-12-27
EP3372281B1 (en) 2021-07-07
MX302718B (es) 2012-08-27
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
MX2007013351A (es) 2008-01-21
KR101580310B1 (ko) 2016-01-04
NZ562339A (en) 2011-01-28
US20190284208A1 (en) 2019-09-19
DK3187225T3 (da) 2022-02-28
ES2743531T3 (es) 2020-02-19
US20170224694A1 (en) 2017-08-10
PL3045206T3 (pl) 2018-08-31
LTC2465580I2 (enExample) 2022-10-10
EP3284520B1 (en) 2019-06-05
US20090318421A1 (en) 2009-12-24
HUS2100022I1 (hu) 2021-07-28
EP3187226A1 (en) 2017-07-05
US8410103B2 (en) 2013-04-02
KR101363875B1 (ko) 2014-02-21
CY2014024I2 (el) 2025-05-09
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
ES2667868T3 (es) 2018-05-14
BRPI0610030A2 (pt) 2011-10-11
US9051337B2 (en) 2015-06-09
US20220213121A1 (en) 2022-07-07
US20170209454A1 (en) 2017-07-27
FR14C0041I2 (fr) 2015-11-13
KR20140097438A (ko) 2014-08-06
EP1874117B8 (en) 2014-03-12
LTPA2021512I1 (enExample) 2021-07-12
SI2465580T1 (sl) 2014-04-30
NL301109I1 (nl) 2021-09-15
NO339525B1 (no) 2016-12-27
CY1120345T1 (el) 2019-07-10
LT3284520T (lt) 2019-09-25
HK1172282A1 (en) 2013-04-19
EP2527007A1 (en) 2012-11-28
LU92446I2 (fr) 2015-10-29
EP3372281A1 (en) 2018-09-12
HUS2100023I1 (hu) 2021-07-28
EP1874117B1 (en) 2013-08-28
ES2892304T3 (es) 2022-02-03
NO2017010I2 (no) 2017-03-27
EP2527007B1 (en) 2016-03-30
US20170267693A1 (en) 2017-09-21
PL2465580T3 (pl) 2014-05-30
ES2906792T3 (es) 2022-04-20
HK1249742A1 (en) 2018-11-09
LTPA2014021I1 (lt) 2014-07-25
IL225206A (en) 2017-11-30
ES2667868T5 (es) 2023-06-01
US20150232479A1 (en) 2015-08-20
JP2008540343A (ja) 2008-11-20
HUE056603T2 (hu) 2022-02-28
EA200702080A1 (ru) 2008-04-28
PT3284520T (pt) 2019-09-10
CA2606282A1 (en) 2006-11-02
US20170145033A1 (en) 2017-05-25
US20170224695A1 (en) 2017-08-10
HUE037795T2 (hu) 2018-09-28
JP4295353B2 (ja) 2009-07-15
IL215788A0 (en) 2011-12-29
CY2014024I1 (el) 2015-12-09
CY1115151T1 (el) 2015-12-09
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
US20130172559A1 (en) 2013-07-04
DK2465580T3 (en) 2014-03-10
US20170029438A1 (en) 2017-02-02
SI3284520T1 (sl) 2019-10-30
US20200339598A1 (en) 2020-10-29
WO2006116764A1 (en) 2006-11-02
CY2021016I2 (el) 2021-12-31
LT3045206T (lt) 2018-06-11
BE2021C519I2 (enExample) 2025-12-10
DK3372281T3 (da) 2021-09-27
EP3187225B1 (en) 2022-01-05
US20160304535A1 (en) 2016-10-20
AU2006239177B8 (en) 2012-02-16
VN34404A1 (en) 2013-07-25
AU2006239177B2 (en) 2011-10-20
LTC1874117I2 (lt) 2025-03-25
AU2006239177A1 (en) 2006-11-02
TWI378931B (en) 2012-12-11
EP3284519A8 (en) 2018-04-18
CY2021016I1 (el) 2021-10-15
EP2465580A1 (en) 2012-06-20
US20190152990A1 (en) 2019-05-23
US8129385B2 (en) 2012-03-06
IL186555A (en) 2016-10-31
US20140200209A1 (en) 2014-07-17
CA2606282C (en) 2016-04-26
NO20161315A1 (no) 2007-11-22

Similar Documents

Publication Publication Date Title
MX312216B (en) Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
IL190879A0 (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
EP1790638A4 (en) CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY
ZA200803423B (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
PL1948666T3 (pl) Inhibitory integrazy HIV
EP1756069A4 (en) HIV INTEGRASE INHIBITORS
IL177189A0 (en) Hiv integrase inhibitors
IL177858A0 (en) Hiv integrase inhibitors
EP1910363A4 (en) INHIBITORS OF HIV INTEGRASE
IL189939A0 (en) Inhibitors of the hiv integrase enzyme
EP1910356A4 (en) HIV integrase
EP1910355A4 (en) HIV integrase
EP1909578A4 (en) INHIBITORS OF HIV INTEGRASE
ZA200606956B (en) HIV integrase inhibitors